Develop, Partner, Acquire or Avoid – Where’s Investment for Digital Pathology Headed in 2023?
![](https://www.signifyresearch.net/wp-content/uploads/2023/10/cropped-hit_consultant_logo-3.png)
![Imogen Fitt headshot](https://www.signifyresearch.net/wp-content/uploads/2023/12/Signify-Imogen_F-Profile-@2-150x150.png)
Imogen Fitt
Published: February 6, 2023 In The News
3rd February 2023 – Imogen Fitt – Featured on hitconsultant.net
News of Fujifilm’s recent acquisition of software provider Inspirata’s digital pathology assets was met with much interest last month, following on from robust industry debate at Global Engage’s Digital Pathology and AI Congress: Europe a few weeks prior. Their discussions centered around the progress of the market and its inevitable future developments.
Whilst our in-depth analysis of the implications of Fujifilm’s specific deal will be released soon as a part of our Premium Insights service, below we outline the wider investment landscape and our own views on what the future holds below.
You may also like